HC Wainwright Comments on Pharming Group Q4 Earnings

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright issued their Q4 2026 earnings estimates for shares of Pharming Group in a research note issued on Tuesday, October 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Pharming Group’s FY2027 earnings at $0.59 EPS.

Other research analysts have also issued research reports about the stock. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a research note on Wednesday. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a report on Wednesday, September 23rd. Weiss Ratings upgraded Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, October 23rd. Finally, Wall Street Zen raised Pharming Group to a “hold” rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharming Group presently has a consensus rating of “Hold” and an average target price of $38.67.

Pharming Group Trading Down 0.3%

PHAR opened at $11.87 on Wednesday. The firm has a market cap of $840.13 million, a price-to-earnings ratio of 98.92 and a beta of -0.05. The stock has a fifty day moving average price of $10.69 and a 200-day moving average price of $13.89. Pharming Group has a 12 month low of $9.11 and a 12 month high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $117.60 million during the quarter, compared to the consensus estimate of $117.60 million.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group accounts for about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors.

Pharming Group News Roundup

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Third-quarter revenue rose 21% year over year to $117.6 million, in line with estimates, while adjusted earnings of $0.30 per share exceeded the $0.15 consensus estimate. Operating profit increased 89% to $29.9 million. Pharming Group earnings results
• Positive Sentiment: Joenja revenue climbed 58% to $23.8 million, supported by strong U.S. and international demand. The company also reported progress toward expansion, including a U.S. pediatric label and launches in Germany and Japan. Pharming third-quarter financial results
• Positive Sentiment: RUCONEST revenue increased 14% to $93.8 million, suggesting demand has stabilized, while operating cash flow strengthened the balance sheet and lifted cash to $190.9 million.
• Positive Sentiment: Pharming expects to release topline Phase II data for leniolisib in the broader common variable immunodeficiency (CVID) population in November. Positive data could expand Joenja’s addressable market, although the result remains a material clinical catalyst. Pharming growth and CVID data
• Neutral Sentiment: Pharming narrowed its 2026 revenue guidance to $380 million-$390 million from $375 million-$395 million. The midpoint is unchanged, so the update signals improved visibility rather than a clear increase in expectations. Pharming Q3 earnings call transcript
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no evidence of meaningful short-covering demand or bearish positioning. Pharming short interest

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.